
The panel opens by defining high-risk localized prostate cancer. One panelist looks at Gleason grade, T stage, spread to the seminal vesicles or lymph nodes, and PSA level.
Four prostate cancer experts discuss ESMO 2026 data on treatment intensification from high-risk localized to metastatic hormone-sensitive disease, choosing among treatments, cognitive effects, options in castration-resistant disease, and EZH2inhibition with mevrometostat.

The panel opens by defining high-risk localized prostate cancer. One panelist looks at Gleason grade, T stage, spread to the seminal vesicles or lymph nodes, and PSA level.

The moderator asks one of the panelists to compare the DASL-HiCaP trial with the STAMPEDE and ENZARAD trials.